S. Chaplin, G. Mcinnes
Mar 5, 2013
Citations
0
Influential Citations
0
Citations
Journal
Prescriber
Abstract
Azilsartan medoxomil (Edarbi) is a new angiotensin‐II receptor blocker for use in the treatment of hypertension. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Gordon McInnes discusses its place in treatment.